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Purpose

Methods

• To evaluate adherence to an organization’s
procedure for Tardive Dyskinesia (TD)
• Data from the electronic medical record
(EMR) was analyzed to determine the
number of times clinicians completed the
electronic Abnormal Involuntary
Movement Scale (AIMS)

• Inclusion criteria all patient/provider
encounters for clients who were taking
antipsychotic medications between
August 19, 2020 and November 26,
2020
• De-identified data included at least one
of the top five most frequently
prescribed antipsychotic medications;
• Data included provider type, practice
settings, encounter date, and whether an
EMR AIMS assessment was completed.

Background and Significance
Tardive Dyskinesia:
• Newer antipsychotic medications from
the 80s up to recent years significantly
decreased tardive dyskinesia.

Other Results

Approximately 3 % of cases are severe

•

Screening using AIMS can reduce these
statistic.1

•

VMAT2 drugs treat TD

AIMS
• A screening instrument designed to detect
TD with a Cronbach alpha score of r-0.97
• Evidence-based practice recommends
annual AIMS screening for all patients
taking antipsychotics

AIMS
completed

AIMS not completed

Total

aripiprazole

27

591

618

olanzapine

23

402

425

risperidone

31

433

464

quetiapine

26

384

410

clozapine

1

249

250

Total

108

2059

2167

Provider
Type

AIMS
Yes

AIMS
No

Visits

Percent

Percent per visits

MD

16

765

781

14.8

1.6

DNP

50

364

414

46.3

8.9

PA

42

924

966

38.9

3,3

unknown

0

6

6

0

0

Total

108

2059

2169

100

Five of the most used antipsychotic medications
were selected from a list of 21 medications.

Antipsychotic Medication Benefit:
• Provide a better quality of a life for
patient with severe mental illnesses
• Provide relief of symptoms of anxiety,
depression, irritability, sleep difficulty
Antipsychotic Medication Risk:
• Cause metabolic diseases such as
diabetes and heart disease
• Cause long term movement disorders

Medication

Provider Type Completing AIMS

Approximately 30 % are moderate to
extreme and of these more than 40 %
have extreme anxiety related to their
symptoms.

•

AIMS and Medications

2167 patients treated with antipsychotic agents
in an outpatient behavioral health clinic.

AIMS Instrument

• TD affects an estimated 500,000 people
in the U.S., 60-70 % of all cases are mild
•

Discussion

Conclusion
5% of 2167 encounters resulted in AIMS
Provider-types:
• MD=Psychiatrists
• PMHNP = psychiatric and mental health
nurse practitioner

Results-AIMS
Table 1: Patient Encounters and AIMS

Total visits without AIMS completed

• PA=Physician’s assistants
Patient
encounters (n)

Percentage
(%)

2059

95

Number of AIMS completed

108

5

Total

2167

100

The data did not reflect any of the AIMS assessment
forms that were manually completed.

( 4 MDs, 1 PMHNP, and 6 PAs)
Of the 2169 encounters
•

781were with MDs

•

966 with a PA

•

414 with the NP (19 %), 12.1 % resulted in
an AIMS screening 46.3 % of the total no.
of AIMS

Recommendations:
• Continuous evaluation of adherence to
clinical practice recommendations
• Give incentives for increased use of the
electronic AIMS form
• Generate quarterly reports from the
electronic health record to show
percentage AIMS completed
electronically
Sustainability and recommendations:
• Develop a system to alert the clinician to
complete monitoring assessments
• Remove paper AIMS forms from clinical
setting
• Provide AIMS education module
• Extend AIMS completion to counselors
Future Needs:
• Conclusive studies showing benefit of
screening
• Improved scoring and
• Consistent and ongoing training for all
staff to create a more collaborative
approach to medication management
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